Name | Carmofur |
Synonyms | hcfu HCFUTM CARMOFUR Carmofur 61422-45-5 5-FLUORO-1-HEXYLCARBAMOYLURACIL 1-(n-Hexylcarbamoyl)-5-fluorouracil 1-(N-HEXYLCARBAMOYL)-5-FLUOROURACIL 3,4-dihydro-2,4-dioxo-5-fluoro-n-hexyl-1(2h)-pyrimidinecarboxamid 5-Fluoro-N-hexyl-2,4-dioxo-3,4-dihydropyrimidine-1(2H)-carboxamide 2,4-dioxo-5-fluoro-n-hexyl-3,4-dihydro-1(2h)-pyrimidinecarboxamidme 1(2H)-pyrimidinecarboxamide, 5-fluoro-N-hexyl-3,4-dihydro-2,4-dioxo- 2,4-dioxo-5-fluoro-n-hexyl-1,2,3,4-tetrahydro-1-pyrimidinecarboxamide |
CAS | 61422-45-5 |
EINECS | 689-431-9 |
InChI | InChI=1/C11H16FN3O3/c1-2-3-4-5-6-13-10(17)15-7-8(12)9(16)14-11(15)18/h7H,2-6H2,1H3,(H,13,17)(H,14,16,18) |
Molecular Formula | C11H16FN3O3 |
Molar Mass | 257.26 |
Density | 1.2287 (estimate) |
Melting Point | 110-111 |
Solubility | DMSO: >15mg/mL |
Appearance | powder |
Color | white to off-white |
Merck | 14,1844 |
pKa | 6.94±0.10(Predicted) |
Storage Condition | 2-8°C |
Refractive Index | 1.525 |
Use | 5-fluorouracil series of the third generation of anticancer drugs, a variety of solid tumors and ascites tumors have a strong inhibitory effect |
In vitro study | Carmofur is one of the masking compounds of 5-FU, which is modified to have more potent antitumor activity and less toxicity. Carmofur is converted to 5-FU in vivo either directly or via intermediates such as 1-(carboxypentylcarbamoyl)-5-fluorouracil and/or 1-(carboxypylcarbomoyl)-5-fluorouraci. Carmofur and its metabolites gradually accumulate in the brain during continuous administration and are cleared very slowly. In clinical and upper brain CT, Carmofur resembles methotrexate white matter with potent neurotoxicity that can produce severe leukoencephalopathy, along with toxic Cerebellar syndrome similar to 5-FU. |
In vivo study | In the tumor tissues of nude mice, Carmofur or 5-FU and Nicardipine, a calcium antagonist, kept FU at a higher level in cancer tissues and enhanced the anti-tumor effect of human gastric cancer. In tumor tissues of nude mice transplanted subcutaneously with parental or 5-FU-resistant DLD-1 cells, Carmofur exerted almost the same growth inhibitory effect. |
Risk Codes | R60 - May impair fertility R61 - May cause harm to the unborn child R25 - Toxic if swallowed |
Safety Description | 45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
UN IDs | UN 2811 6.1 / PGII |
WGK Germany | 3 |
RTECS | UV7714000 |
HS Code | 29335990 |
Hazard Note | Irritant |
Hazard Class | 6.1 |
Packing Group | III |
This product is n-hexyl-5-fluoro-3, 4-dihydro-2, 4-dioxo-1 (2H)-pyrimidine formamide. Calculated as dry product, containing C11H16FN303 should be 98.5% ~ 101.5%.
The melting point of this product (General rule 0612) is 110~114°C, and it is decomposed at the same time during melting.
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.887 ml | 19.436 ml | 38.871 ml |
5 mM | 0.777 ml | 3.887 ml | 7.774 ml |
10 mM | 0.389 ml | 1.944 ml | 3.887 ml |
5 mM | 0.078 ml | 0.389 ml | 0.777 ml |
take 2.og of this product, add 100ml of water, shake for 15 minutes, filter, take the filtrate 25ml, check according to law (General rule 0801), and compare with the control solution made of 5.0ml of standard gasification sodium solution, no more concentrated (0.01%).
take 50ml of the filtrate remaining under the above chloride item and check it according to law (General rule 0802). Compared with the control solution made of 0.02% of standard potassium sulfate solution, it should not be more concentrated ().
fluorine content
take this product about 30mg, precision weighing, according to the fluorine inspection method (General 0805) determination, fluorine content should be 6. 6% ~ 7.4%.
take this product, quantitatively dissolve it with methanol-glacial acetic acid (99:1) and make a solution containing about 20mg per 1 ml as the test solution; Take appropriate amount with precision, quantitative dilution with methanol-glacial acetic acid (99:1) was made to contain 0.1 mg solution, as a control solution. According to the thin layer chromatography (General 0502) test, draw 15ul of each of the above two solutions, respectively point on the same silica gel GF254 thin layer plate, with toluene-acetone (5:3) as the developing solvent, open, dry, and set the UV light (254nm) to view. Test solution such as impurity spots, compared with the control solution of the main spot, not deeper.
take this product, put it in a phosphorus pentoxide dryer, and dry it under reduced pressure at 60°C to constant weight, and the weight loss shall not exceed 0.3% (General rule 0831).
take 0.50g of this product, add water to 3.5, shake for 15 minutes, filter, add acetate buffer (pH 0821) 2ml to the filtrate, add water to, and check according to law (General rule first law), heavy metals should not be more than 20 parts per million.
take this product about 0.2g, precision weighing, add N,N-dimethylformamide 10ml to dissolve, add 5 drops of anhydrous methanol solution of 0.3% Thymol Blue, with tetrabutylammonium hydroxide titration solution (0.1 mol/L) was titrated to blue and the results of the titration were corrected with a blank test. Each 1 ml of tetrabutylammonium hydroxide titration solution (0.1 mol/L) corresponds to 25.73mg of C11H16FN303.
antineoplastic agents.
light shielding, sealed storage.
This product contains carmofur (C11H16FN303) should be labeled the amount of 90.0% to 110.0%.
This product is white tablet.
with carmofur.
50mg
light shielding, sealed storage.
pharmacodynamics | carmofur is a derivative of fluorouracil, which is rapidly absorbed orally and slowly releases Fluorouracil in vivo, interference or blocking DNA, RNA and protein synthesis to play an anti-tumor effect. |
pharmacokinetics | after oral administration, carmofur can be metabolized in various ways in vivo, and gradually release 5-fluorouracil, and can maintain Fluorouracil in the effective blood concentration range for a long time, Tmax2-4 hours, liver, kidney and stomach wall concentration is higher, mainly by the urine discharge. |
effect | carmofur is an oral antineoplastic drug, belonging to pyrimidine antimetabolites. It is a derivative of fluorouracil. This product has the advantages of low toxicity and wide anti-tumor spectrum. Clinically used for gastric cancer, colon cancer, breast cancer, can make the cancer significantly reduced, especially for colon cancer with high efficiency, through the slow release of Fluorouracil in the body and play an anti-tumor effect. |
indication | It is mainly used for digestive tract cancer such as gastric cancer, colorectal cancer, liver cancer, etc. |
biological activity | Carmofur (HCFU) is a Pyrimidine analog that is used as an antineoplastic agent. |
Target | Value |
Use | is the third generation anticancer drug of 5-fluorouracil series, it has strong inhibitory effect on a variety of solid tumors and ascites tumors. |
category | toxic substances |
toxicity grade | high toxicity |
Acute toxicity | oral-rat LD50: 268 mg/kg; Oral-mouse LD50: 1129 mg/kg |
flammability hazard characteristics | thermal decomposition of toxic nitrogen oxides, fluoride smoke |
storage and transportation characteristics | The warehouse is ventilated and dried at low temperature; It is stored separately from food raw materials |
fire extinguishing agent | water, carbon dioxide, foam, dry powder |